Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Raw Materials (2021 - 2025)

Fortress Biotech (FBIO) has 5 years of Raw Materials data on record, last reported at $2.8 million in Q1 2025.

  • For Q1 2025, Raw Materials fell 32.82% year-over-year to $2.8 million; the TTM value through Mar 2025 reached $2.8 million, down 32.82%, while the annual FY2024 figure was $3.2 million, 31.12% down from the prior year.
  • Raw Materials reached $2.8 million in Q1 2025 per FBIO's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Raw Materials topped out at $8.4 million in Q1 2022 and bottomed at $2.8 million in Q1 2025.
  • Average Raw Materials over 5 years is $5.2 million, with a median of $5.1 million recorded in 2021.
  • Peak YoY movement for Raw Materials: surged 46.89% in 2022, then tumbled 34.53% in 2023.
  • A 5-year view of Raw Materials shows it stood at $5.6 million in 2021, then grew by 15.83% to $6.5 million in 2022, then dropped by 28.11% to $4.6 million in 2023, then crashed by 31.12% to $3.2 million in 2024, then fell by 12.14% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $2.8 million in Q1 2025, $3.2 million in Q4 2024, and $3.6 million in Q3 2024.